FDA hits Chinese drugmaker with warning letter over manufacturing issues

FDA hits Chinese drug manufacturer Wuxi Medical Instrument Factory with a warning letter.

The FDA served a warning letter to China’s Wuxi Medical Instrument Factory in response to an inspection that exposed four violations, including an infringement on procedures that involved company employees misrepresenting to inspectors the actual dates of the creation of some documents.

The inspection at the Wuxi City-based facility took place in early March.

During the inspection, the agency said in a letter to the company posted on its website this week, the FDA found that records covering January to March of this year were signed by two employees that stated sanitization had been completed and verified contemporaneously during those months.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

“However, our investigator found that these operations were not documented at the time of their actual performance, but were instead created and completed on March 7, 2017, the second day of the inspection," the letter said.

The regulatory agency also said it found Wuxi Medical Instrument Factory was unable to provide process qualification batch records and quality control test documentation, and only gave inspectors "a protocol and a summary report with insufficient data.”

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.